Brokerages Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Target Price at $3.75

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have received a consensus rating of “Hold” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $3.75.

A number of equities research analysts have recently commented on HOWL shares. Weiss Ratings cut shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th.

Insider Transactions at Werewolf Therapeutics

In related news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $0.35, for a total transaction of $145,918.85. Following the completion of the sale, the insider directly owned 303,719 shares in the company, valued at approximately $106,301.65. This trade represents a 57.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Luke Evnin sold 76,928 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $0.37, for a total transaction of $28,463.36. Following the sale, the director owned 300,283 shares of the company’s stock, valued at approximately $111,104.71. The trade was a 20.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,924,038 shares of company stock valued at $2,025,440 over the last quarter. Company insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Regal Investment Advisors LLC increased its position in Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. increased its position in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics during the second quarter worth about $48,000. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics during the first quarter worth about $79,000. Finally, Bridgeway Capital Management LLC increased its position in Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL opened at $0.32 on Monday. The firm has a 50-day simple moving average of $0.54 and a 200-day simple moving average of $0.67. The stock has a market capitalization of $15.70 million, a price-to-earnings ratio of -0.26 and a beta of 0.29. Werewolf Therapeutics has a 52 week low of $0.31 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. As a group, equities research analysts expect that Werewolf Therapeutics will post -1.08 EPS for the current year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.